Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis

Hu, Lingbo; Zheng, Yu; Lin, Jiangyin; Shi, Xingpeng; Wang, Aidong

doi:10.1016/j.clinre.2022.102061

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang et al analyzed 12 studies containing 3510 patients and revealed that lenvatinib was associated with numerically better OS (HR: 0.85; 95% CI 0.73–0.99; P = 0.075), PFS (HR: 0.72; 95% CI 0.61–0.84; P = 0.066), DCR (OR: 2.23; 95% CI 1.70–2.93; P = 0.098), and significantly higher ORR (OR: 4.25; 95% CI 2.78–6.48; P = 0.045) compared with sorafenib [ 95 ]. Similarly, Hu et al conducted a meta-analysis of 9 studies comprising 1914 patients and found that lenvatinib vs. sorafenib had improved OS (HR: 0.87; 95% CI 0.78–0.97), PFS (HR: 0.67; 95% CI 0.48–0.94), ORR (OR: 7.44; 95% CI 4.44–12.46), and DCR (OR: 4.57; 95% CI 2.3–9.07) [ 96 ].…”

Section: Comparison Of the Outcomes Of Approved Small Molecule Tkis F...mentioning

confidence: 99%

“…The severe AE rate was similar in the lenvatinib and sorafenib groups [ 93 – 95 ], but lenvatinib was significantly associated with a higher incidence of hypertension, proteinuria, fatigue, decreased appetite, and weight loss, whereas sorafenib was associated with a higher incidence of diarrhea and HFSR [ 94 , 96 ].…”

Section: Comparison Of the Outcomes Of Approved Small Molecule Tkis F...mentioning

confidence: 99%

See 1 more Smart Citation

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Liu,

Xia,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death in the world, and hepatocellular carcinoma (HCC) is the most common form of liver cancer. More than half of the HCC patients are diagnosed at an advanced stage and often require systemic therapy. Dysregulation of the activity of receptor tyrosine kinases (RTKs) is involved in the development and progress of HCC, RTKs are therefore the potential targets for systemic therapy of advanced HCC (aHCC). Currently, a total of six small molecule tyrosine kinase inhibitors (TKIs) have been approved for aHCC, including first-line sorafenib, lenvatinib, and donafenib, and second-line regorafenib, cabozantinib, and apatinib. These TKIs improved patients survival, which are associated with disease stage, etiology, liver function, tumor burden, baseline levels of alpha-fetoprotein, and treatment history. This review focuses on the clinical outcomes of these TKIs in key clinical trials, retrospective and real-world studies and discusses the future perspectives of TKIs for aHCC, with an aim to provide up-to-date evidence for decision-making in the treatment of aHCC.

show abstract

Section: Comparison Of the Outcomes Of Approved Small Molecule Tkis F...mentioning

confidence: 99%

Section: Comparison Of the Outcomes Of Approved Small Molecule Tkis F...mentioning

confidence: 99%

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives

Liu,

Xia,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

“…The effective therapy from LVN gains large attention from clinicians. Herein, the question of LVN resistance has naturally become a hot topic for scientists to study, no matter in the cancer types of RCC, HCC or DTC ( Hu et al, 2022a ; Persano et al, 2022 ). At present, LVN has achieved good efficacy in the targeted therapy of many cancer types ( Su et al, 2022a ; Wassermann et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%